Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
2
40%
Ph phase_4
2
40%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 42 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

Belimumab Assessment of Safety in SLE

NCT01705977
completedphase_3

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

NCT04082416
completedphase_4

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

NCT01632241
completedphase_3

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

NCT01639339
completedphase_2

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

NCT02885610

Clinical Trials (5)

Showing 5 of 5 trials
NCT01705977Phase 4

Belimumab Assessment of Safety in SLE

Completed
NCT04082416Phase 3

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Completed
NCT01632241Phase 4

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

Completed
NCT01639339Phase 3

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Completed
NCT02885610Phase 2

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5